Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Bar Code Medication Administration Technology: A Systematic Review of Impact on Patient Safety When Used with Computerized Prescriber Order Entry and Automated Dispensing Devices.

Shah K, Lo C, Babich M, Tsao NW, Bansback NJ.

Can J Hosp Pharm. 2016 Sep-Oct;69(5):394-402. Epub 2016 Oct 31. No abstract available.

2.

Decentralized automated dispensing devices: systematic review of clinical and economic impacts in hospitals.

Tsao NW, Lo C, Babich M, Shah K, Bansback NJ.

Can J Hosp Pharm. 2014 Mar;67(2):138-48. Review.

3.

Cost-effectiveness of newer antiretroviral drugs in treatment-experienced patients with multidrug-resistant HIV disease.

Bayoumi AM, Barnett PG, Joyce VR, Griffin SC, Sun H, Bansback NJ, Holodniy M, Sanders G, Brown ST, Kyriakides TC, Angus B, Cameron DW, Anis AH, Sculpher M, Owens DK.

J Acquir Immune Defic Syndr. 2013 Dec 1;64(4):382-91. doi: 10.1097/QAI.0000000000000002.

4.

The issue of comparators in economic evaluations of biologic response modifiers in rheumatoid arthritis.

Tsao NW, Bansback NJ, Shojania K, Marra CA.

Best Pract Res Clin Rheumatol. 2012 Oct;26(5):659-76. doi: 10.1016/j.berh.2012.07.012. Review.

PMID:
23218430
5.

Cost-effectiveness of diacetylmorphine versus methadone for chronic opioid dependence refractory to treatment.

Nosyk B, Guh DP, Bansback NJ, Oviedo-Joekes E, Brissette S, Marsh DC, Meikleham E, Schechter MT, Anis AH.

CMAJ. 2012 Apr 3;184(6):E317-28. doi: 10.1503/cmaj.110669. Epub 2012 Mar 12.

6.

Valuing health for clinical and economic decisions: directions relevant for rheumatologists.

Harrison MJ, Bansback NJ, Marra CA, Drummond M, Tugwell PS, Boonen A.

J Rheumatol. 2011 Aug;38(8):1770-5. doi: 10.3899/jrheum.110404.

PMID:
21807800
7.

Exploring the validity of estimating EQ-5D and SF-6D utility values from the health assessment questionnaire in patients with inflammatory arthritis.

Harrison MJ, Lunt M, Verstappen SM, Watson KD, Bansback NJ, Symmons DP.

Health Qual Life Outcomes. 2010 Feb 11;8:21. doi: 10.1186/1477-7525-8-21.

8.

Development of a population-based microsimulation model of osteoarthritis in Canada.

Kopec JA, Sayre EC, Flanagan WM, Fines P, Cibere J, Rahman MM, Bansback NJ, Anis AH, Jordan JM, Sobolev B, Aghajanian J, Kang W, Greidanus NV, Garbuz DS, Hawker GA, Badley EM.

Osteoarthritis Cartilage. 2010 Mar;18(3):303-11. doi: 10.1016/j.joca.2009.10.010. Epub 2009 Oct 23.

9.

The comparative responsiveness of the EQ-5D and SF-6D to change in patients with inflammatory arthritis.

Harrison MJ, Davies LM, Bansback NJ, McCoy MJ, Verstappen SM, Watson K, Symmons DP; British Society for Rheumatology Biologics Register Control Centre Consortium.

Qual Life Res. 2009 Nov;18(9):1195-205. doi: 10.1007/s11136-009-9539-2. Epub 2009 Sep 24.

10.

Why do patients with inflammatory arthritis often score states "worse than death" on the EQ-5D? An Investigation of the EQ-5D classification system.

Harrison MJ, Davies LM, Bansback NJ, McCoy MJ, Farragher TM, Verstappen SM, Hassell A, Symmons DP.

Value Health. 2009 Sep;12(6):1026-34. doi: 10.1111/j.1524-4733.2009.00565.x. Epub 2009 May 15.

11.

Patient reported outcomes for rheumatoid arthritis: where are we and where are we going?

Bansback NJ, Anis AH, Marra CA.

J Rheumatol. 2008 Aug;35(8):1482-3. No abstract available.

PMID:
18671320
12.

The validity and responsiveness of generic utility measures in rheumatoid arthritis: a review.

Harrison MJ, Davies LM, Bansback NJ, Ingram M, Anis AH, Symmons DP.

J Rheumatol. 2008 Apr;35(4):592-602. Epub 2008 Feb 15. Review.

PMID:
18278841
13.

Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis.

Bansback NJ, Ara R, Barkham N, Brennan A, Fraser AD, Conway P, Reynolds A, Emery P.

Rheumatology (Oxford). 2006 Aug;45(8):1029-38. Epub 2006 Jun 16.

PMID:
16782734
14.

The impact of age-related macular degeneration on health status utility values.

Espallargues M, Czoski-Murray CJ, Bansback NJ, Carlton J, Lewis GM, Hughes LA, Brand CS, Brazier JE.

Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4016-23.

PMID:
16249475
15.

An overview of economic evaluations for drugs used in rheumatoid arthritis : focus on tumour necrosis factor-alpha antagonists.

Bansback NJ, Regier DA, Ara R, Brennan A, Shojania K, Esdaile JM, Anis AH, Marra CA.

Drugs. 2005;65(4):473-96. Review.

PMID:
15733011
16.

Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden.

Bansback NJ, Brennan A, Ghatnekar O.

Ann Rheum Dis. 2005 Jul;64(7):995-1002. Epub 2004 Nov 18.

17.

The NICE reappraisal of biologics in 2005: what rheumatologists need to know.

Bansback NJ, Young A, Brennan A.

Rheumatology (Oxford). 2005 Jan;44(1):3-4. Epub 2004 Aug 24. No abstract available.

PMID:
15328422

Supplemental Content

Loading ...
Support Center